On a clinical level, the study suggests that physicians prescribing Lumakras should remain vigilant for early signs of ILD, especially in patients with lung comorbidities. Additionally, biomarker ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback